Key facts
- vVardis reported a net loss of $27.8 million on revenue of $28.6 million for the six months ended June 30, 2026.
- This compares to a net loss of $32.1 million on revenue of $9.1 million in the same period a year ago.
- The company's products have been sold to over 20,000 of the approximately 110,000 general dental practices in the US as of June 30.
- vVardis plans to list its shares on the NYSE under the symbol "VVVV".
Dental technology company vVardis has revealed a significant increase in revenue for the first half of the year as it pursues an initial public offering in the US. The company reported a net loss of $27.8 million on revenue of $28.6 million for the six months ended June 30, 2026. This marks an improvement from the same period in the prior year, when it posted a net loss of $32.1 million on revenue of $9.1 million.
vVardis, founded by dentists Haley Abivardi and Goly Abivardi, specializes in developing non-invasive treatments for early-stage cavities. As of June 30, its products had reached more than 20,000 of the approximately 110,000 general dental practices in the United States.
The filing comes at a time when the US IPO market is being selective, with investors closely scrutinizing valuations. However, healthcare and pharmaceutical companies have generally remained resilient to broader macroeconomic uncertainties. Medical device maker Centinel Spine also recently filed for an IPO.
Backers of vVardis include healthcare investor OrbiMed, Heartland Dental, and affiliates of Apollo Global Management. The company plans to use the proceeds from its IPO for working capital, operating expenses, and capital expenditures. Goldman Sachs, J.P. Morgan, William Blair, UBS Investment Bank, Deutsche Bank Securities, and Apollo Global Securities are serving as underwriters for the offering. vVardis intends to list its shares on the New York Stock Exchange under the symbol "VVVV".